High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Multiple myeloma, for all practical purposes, remains an incurable malignancy; however, 5-year survival has improved substantially during the past 30 years. A major contribution to improved outcome is the use of high-dose chemotherapy and stem cell transplantation. This multifaceted approach to therapy requires an understanding of appropriate induction therapy, techniques for stem cell mobilization, appropriate conditioning and supportive care. Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy.
Gertz
Morie A
MA
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
Lacy
Martha Q
MQ
Dispenzieri
Angela
A
Hayman
Suzanne R
SR
Kumar
Shaji K
SK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D018579:Patient Selection; D011379:Prognosis; D011788:Quality of Life; D016019:Survival Analysis; D014182:Transplantation, Autologous